PRIMARY & SECONDARY PREVENTION OF CHD
The USPSTF issued new guidance on the use of aspirin for primary prevention of cardiovascular events; patients aged 40–49 years should have a shared decision-making conversation regarding the potential risks and benefits of initiating aspirin therapy for primary prevention, and patients aged 60 years or older should not initiate aspirin for primary prevention of CVD.
CHRONIC STABLE ANGINA PECTORIS
CT-functional fractional reserve (CT-FFR) has been approved for clinical use and has been endorsed with a level IIa recommendation for intermediate-risk patients with chest pain and no prior history of CAD with a 40–90% stenosis on CT imaging to guide need for revascularization.
Writing Committee Members; Gulati M et al. J Am Coll Cardiol. [PMID: 34756653]
The FDA approved sacubitril/valsartan in patients with heart failure and preserved LVEF, particularly for patients with an EF less than 50%, including patients with a mildly reduced EF of 41–49%.
Empagliflozin has been FDA-approved to treat heart failure with reduced LVEF, with or without diabetes; it is the only therapy shown to reduce cardiovascular death or heart failure hospitalization in this population.
McDonagh TA et al. Eur J Heart Fail. [PMID: 35083827]
Bozkurt B et al. J Card Fail. [PMID: 33663906]
Myocarditis following infection with SARS-CoV-2 infection and following vaccination have been reported in the medical literature. In both scenarios, younger male patients seem to be at highest risk for this overall rare event.
Boehmer TK et al. MMWR Morb Mortal Wkly Rep. [PMID: 34473684]
Witberg G et al. N Engl J Med. [PMID: 34614329]